No Data
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Anixa Biosciences Enters JV With Cleveland Clinic for Additional Cancer Vaccines
Anixa Biosciences Forms Cancer Vaccine Partnership With Cleveland Clinic
Anixa Biosciences Partners With Cleveland Clinic To Develop Cancer Vaccines
Anixa Biosciences Partners With Cleveland Clinic To Develop Cancer Vaccines
Anixa Biosciences Expands Partnership With Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX